China Accepts United Labs' Semaglutide Biosimilar Application for Second Indication; Shares up 5%

MT Newswires Live11-05

United Laboratories International Holdings (HKG:3933) said Chinese regulators have accepted its marketing application for the Semaglutide biosimilar injection, indicated for weight management, according to a Wednesday bourse filing.

The company said it filed a marketing application in January last year for the same product, which was also accepted, but indicated it for diabetes.

Shares were last up 5.3% Thursday afternoon.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment